Inotek Pharmaceuticals Corp. (ITEK) stock coverage initiated with “Buy” in note to investors by Roth Capital

Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) shares rose on Thursday Dec 1 with lighter trade volume than normal after more analysts initiated coverage on the stock.

Meanwhile, U.S. stocks opened with slight gains on Thursday.

The Dow Jones Industrial Average DJIA, +0.31% rose 38.22 points, or 0.2%, to 19,174, while the S&P 500 SPX, +0.01% added 2.1 points to 2,202, a rise of 0.1%.

The Nasdaq Composite Index COMP, -0.32% rose less than 1 point to 5,323, essentially unchanged on the day.
Analysts at Roth Capital initiated coverage on Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) stock, starting the company at Buy. Roth Capital currently has a rating of Buy on the shares. As a means of comparison, a number of other analysts have commented on the company in recent days, and the company has secured a consensus one-year price target of $29.00, higher than the opening price of $6.55. Inotek Pharmaceuticals Corp. stock has a 52-week high of $12.41. Changes in price targets are not unheard of as analysts and brokerage firms will issue periodic updates after initiating coverage,.

Shares of Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) opened at $6.55 on Tuesday and has traded in a range between, $6.40 and $6.60, and last traded at $6.45, which represents a jump of $0.05 or 0.78% over the previous closing price.

Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) now has a market cap of 173.70M.

Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) Average Daily Trading Volume

The stock’s average daily volume is 278,492 shares out of a total float 12,753,000 and some 41,016 shares crossed the trading desk yesterday, below the norm. Look for trading volume to pick up in the coming days as investors often use swings in trading volume to identify large volume aggregation or circulation by institutional investors.

However, a single day of heavy buy side trading is not enough to assert a trend. As such, market traders will continue to look for institutional sponsorship as a signal that financial institutions are moving forward.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Institutional investors such as these have substantial teams of analysts that investigate thousands of stocks, so it is good validation to see them buying a stock you are researching.

Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) Moving Averages

A moving average can also act as support or resistance. In an uptrend a 50-day, 100-day or 200-day moving average may act as a support level, as shown in the figure below.

This is because the average acts like a floor (support), so the price bounces up off of it.

In a downtrend a moving average may act as resistance; like a ceiling, the price hits it and then starts to drop again.

By tracking the activity of these professional investors and how they affect moving averages,it allows for traders to make more useful judgments on trades.

Trades for Inotek Pharmaceuticals Corp. (NASDAQ: ITEK) have ranged from $5.81 – 12.41, and the stock now has a 50-day MA of $7.11 and 200-day MA of $7.84. Today’s last price is 48.03%% below the 52 week high of $12.41.

Earnings growth is a critical factor to consider when buying stocks and investors look for companies that have grown their earnings at least 25% or more over a 3 year period.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published. Required fields are marked *